Skip to main content
Signal8

Abpro Holdings, Inc. (ABPO)

Abpro Holdings, Inc. is a biotechnology firm specializing in the creation of innovative antibody treatments, primarily targeting immuno-oncology and ophthalmology. The company leverages two proprietary technological platforms: DiversImmune, a discovery platform that identifies a broad spectrum of unique antibodies against both established and emerging therapeutic targets, and MultiMab, an engineering platform offering the versatility to assemble antibody components into customized, multi-specific constructs tailored for specific therapeutic needs. Abpro's flagship therapeutic pipeline includes ABP-102, a next-generation immuno-oncology TetraBi antibody engineered to dually target HER2 and CD3, offering a potential treatment for HER2-positive solid tumors like breast and gastric cancers. Another key candidate, ABP-201, is a TetraBi antibody designed to simultaneously inhibit both VEGF and ANG-2 pathways for the management of vascular eye diseases, such as diabetic macular edema and wet age-related macular degeneration. The company's pipeline also features ABP-110, a TetraBi antibody targeting GPC3 and CD3 for hepatocellular carcinoma, and ABP-150, another TetraBi antibody focused on claudin 18.2 and CD3 for gastric cancers. Abpro maintains strategic alliances with Celltrion Inc. and Abpro Bio International, Inc. Established in 2004, Abpro Holdings, Inc. is headquartered in Woburn, Massachusetts.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Abpro Holdings, Inc. logo

Abpro Holdings, Inc.

OTC:ABPOOTC (delisted from Nasdaq, Form 25 effective Oct 10, 2026)Healthcare
AH+0.00%$0.5337
Close$0.5337+0.70%
Mkt Cap$3.15M
EV-
Float5.01M
O/S5.9M
VOL23K sh
$ Vol$12K
RVOL1.36×
Inst Own0.3%
SI0.3%
Net Cash/Sh-
Dilution
Abpro Holdings, Inc. logoOTC:ABPOAH$0.5337+0.00%

Abpro Holdings, Inc. (ABPO) dilution facts from SEC filings

Snapshot as of Jun 30, 2026, built from 17 SEC filings.

Shelf registration
None on file in the filings reviewed
At-the-market (ATM) program
No active program in the filings reviewed
Warrants outstanding
3 warrant series recorded as outstanding
Most recent offering
Offering, closed Nov 7, 2025
Source: S-1/A filed Nov 28, 2025

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro